HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Acute promyelocytic leukemia, FAB M3 — Clinical Guidelines

Overview

Acute promyelocytic leukemia (APML), also known as FAB M3, is a subtype of acute myeloid leukemia characterized by a specific chromosomal translocation (PML-RARA) leading to differentiation arrest at the promyelocyte stage. Early recognition and prompt initiation of treatment with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) are critical for improved outcomes 1 3 10.

Diagnosis

Clinical Presentation: Neuro-ophthalmologic signs, skin lesions (e.g., petechiae, ecchymoses), bone marrow failure symptoms (bruising, epistaxis, fatigue) 1 3.

Laboratory Tests: Peripheral blood smear showing numerous promyelocytes, bone marrow biopsy confirming APML with PML-RARA fusion 1 3.

Genetic Testing: Confirmatory molecular analysis for PML-RARA fusion transcript 1 3.

Management

First-Line Treatment: ATRA combined with anthracycline chemotherapy (e.g., idarubicin) 9.

Adjunctive Therapy: Arsenic trioxide (ATO) for consolidation and maintenance therapy 9 10.

Supportive Care: Management of coagulopathy, infection prophylaxis, and monitoring for retinoic acid syndrome 5 10.

Retinoic Acid Syndrome: Recognize and manage with dexamethasone, hydration, and supportive care 10.

Special Populations

Renal Failure: Monitor ATRA levels during dialysis; consider alternative dialysis modalities if necessary 8.

Obesity: Higher BMI correlates with increased risk of relapse and differentiation syndrome 7.

Key Recommendations

Immediate Initiation of ATRA and Anthracycline Chemotherapy upon diagnosis to improve survival rates (Evidence: Strong 9).

Monitor for and Manage Retinoic Acid Syndrome proactively with dexamethasone and supportive measures (Evidence: Strong 10).

Consider BMI in Risk Stratification for relapse and differentiation syndrome in APML patients (Evidence: Moderate 7).

Genetic Confirmation of PML-RARA fusion is essential for definitive diagnosis (Evidence: Strong 1 3).

Supportive Measures including coagulation management and infection prophylaxis are critical adjuncts to primary therapy (Evidence: Moderate 5 10).

References

1 Paxton AB, Micieli JA. Diagnosis of Acute Promyelocytic Leukemia After Presentation to Neuro-Ophthalmology. Journal of neuro-ophthalmology : the official journal of the North American Neuro-Ophthalmology Society 2022. link 2 Hino C, Ran-Castillo D, Akhtari M, Cao H, Silvestre J. Role of Ketamine and Opioid Rotation in the Management of Opioid Induced Hyperalgesia in a Patient With Acute Promyelocytic Leukemia. Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners 2022. link 3 Stavrou C, Mackenzie S, Pocock R, Wilson AJ. PEACE in the midst of an emergency: a rash not to miss. BMJ case reports 2020. link 4 Polaina-Rusillo M, Pérez-del Barrio Mdel P, Carrillo-Colmenero AM, Ramírez-Tortosa C, Borrego-Hinojosa J, Liébana-Cañada A. Renal cortical necrosis secondary to thrombotic microangiopathy in the context of acute promyelocytic leukaemia blast crisis. Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 2013. link 5 Avvisati G. Coagulopathy in APL: a step forward?. Blood 2012. link 6 Thomas M, Sukhai MA, Kamel-Reid S. An emerging role for retinoid X receptor α in malignant hematopoiesis. Leukemia research 2012. link 7 Breccia M, Mazzarella L, Bagnardi V, Disalvatore D, Loglisci G, Cimino G et al.. Increased BMI correlates with higher risk of disease relapse and differentiation syndrome in patients with acute promyelocytic leukemia treated with the AIDA protocols. Blood 2012. link 8 Rajpurkar M, Alcasabas P, Warrier I, Valentini RP, Fassinger N, Frattarelli DA et al.. Effect of dialysis on all trans retinoic acid levels in a child with acute promyelocytic leukemia and renal failure. Pediatric blood & cancer 2007. link 9 Sanz MA, Lo Coco F. Standard practice and controversial issues in front-line therapy of acute promyelocytic leukemia. Haematologica 2005. link 10 Fenaux P, De Botton S. Retinoic acid syndrome. Recognition, prevention and management. Drug safety 1998. link 11 Krishnan EU, Wegner K, Garg SK. Congenital hypoplastic anemia terminating in acute promyelocytic leukemia. Pediatrics 1978. link 12 Stavem P, Ly B, Egeberg O, Bull O. Flaming promyelocytes in acute hypergranular promyelocytic leukaemia. Light and electron microscopic study. Scandinavian journal of haematology 1977. link

Acute promyelocytic leukemia, FAB M3